The therapy targets CD19+ B cells, offering a new mechanism for managing this multiorgan fibroinflammatory disease.

Ocrevus rapidly depletes immune B-cells in people with MS, but ongoing treatment also leads to changes in immune T-cells, a study found.

New data suggest the potential of the CAR T-cell therapy obe-cel as a definitive treatment for R/R B-cell acute lymphoblastic ...

For immune cells, the actin cytoskeleton is more than a structural scaffold. Immune cells can migrate to sites of infection ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...